Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement
- 6 June 2000
- journal article
- clinical trial
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 132 (11) , 853-861
- https://doi.org/10.7326/0003-4819-132-11-200006060-00002
Abstract
The optimal duration of prophylaxis against venous thromboembolism after total hip or knee replacement is uncertain. To determine the efficacy and safety of extended out-of-hospital prophylaxis with low-molecular-weight heparin (ardeparin sodium). Randomized, double-blind, placebo-controlled trial. 33 community, university, or university-affiliated hospitals. 1195 adults who had elective total hip or knee replacement and completed 4 to 10 days of postoperative ardeparin prophylaxis. Daily subcutaneous ardeparin (100 IU/kg of body weight) or placebo from time of hospital discharge to 6 weeks after surgery. Symptomatic, objectively documented venous thromboembolism or death, along with major bleeding, from time of hospital discharge to 12 weeks after surgery. Patients who received ardeparin (n = 607) and those who received placebo (n = 588) did not differ significantly in the cumulative incidence of venous thromboembolism or death (9 cases [1.5%] compared with 12 cases [2.0%]; odds ratio, 0.7 [95% CI, 0.3 to 1.7]; P > 0.2; absolute difference, −0.56 percentage points [CI, −2.2 to 1.1 percentage points]) or major bleeding (2 cases [0.3%] compared with 3 cases [0.5%]). Among patients who had total knee or total hip replacement and received 4 to 10 days of postoperative ardeparin prophylaxis, the cumulative incidence of symptomatic venous thromboembolism or death after hospital discharge was not significantly reduced by extended out-of-hospital ardeparin prophylaxis. Extended ardeparin use could provide a maximum 2.2–percentage point true reduction in such events. The benefit of extended ardeparin use is not clinically important for most patients. Future research should identify high-risk patients who would benefit most from extended prophylaxis. *For members of the Ardeparin Arthroplasty Study Group, see Appendix.Keywords
This publication has 12 references indexed in Scilit:
- Postthrombotic Syndrome After Hip or Knee ArthroplastyArchives of internal medicine (1960), 2000
- Prevention of Venous ThromboembolismChest, 1998
- The Incidence of Symptomatic Venous Thromboembolism During and After Prophylaxis With EnoxaparinA Multi-institutional Cohort Study of Patients Who Underwent Hip or Knee ArthroplastyArchives of internal medicine (1960), 1998
- Efficacy and Safety of Prolonged Thromboprophylaxis with a Low Molecular Weight Heparin (Dalteparin) after Total Hip Arthroplasty— The Danish Prolonged Prophylaxis (DaPP) StudyThrombosis Research, 1998
- Ultrasonographic Screening before Hospital Discharge for Deep Venous Thrombosis after Arthroplasty: The Post-Arthroplasty Screening Study: A Randomized, Controlled TrialAnnals of Internal Medicine, 1997
- Low-Molecular-Weight Heparin (Enoxaparin) as Prophylaxis against Venous Thromboembolism after Total Hip ReplacementNew England Journal of Medicine, 1996
- Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placeboThe Lancet, 1996
- RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group.Journal of Bone and Joint Surgery, 1994
- Value of the Ventilation/Perfusion Scan in Acute Pulmonary EmbolismJAMA, 1990
- Some Methods for Strengthening the Common χ 2 TestsPublished by JSTOR ,1954